CGS Shares Cogstate Limited
STRONG BUY ASX · ASXDigital cognitive-testing growth and broker support offer speculative upside as clinical adoption expands.
Future value: $4.41 (+28.93%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Morgans buy rating with $4.07 target
- ▸Above 50-day MA (+4.39%)
- ▸Above 200-day MA — long-term uptrend
- ▸~29% upside to price target
Is CGS a buy right now?
Trend: CGS is trading above the 50-day average (+3.64%), RSI 52 — neutral momentum, with a 3-month return of +36.80%.
Valuation & quality: Cogstate Limited trades on a trailing P/E of 34.2, forward P/E 21.4, price-to-book 7.01; fundamentals show net margin 19.5%, return on equity 22.5%, revenue growth 16.5% year on year.
Analyst consensus: 4 analysts have a mean 12-month price target of A$4.50 (+31.5% vs the last close; range A$3.99 – A$5.80), consensus rating “strong buy”.
Income: trailing dividend yield 1.15%.
Our screen: STRONG BUY (score 5) — Digital cognitive-testing growth and broker support offer speculative upside as clinical adoption expands.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -5.20% | +14.30% | +2.80% | +7.10% | -8.40% | +23.20% | +10.70% | +0.30% |
Fundamentals
Analyst price target
Technical signals
About Cogstate Limited
Cogstate Limited, a neuroscience solutions company, engages in the creation, validation, and commercialization of digital brain health assessments worldwide.
Sector: Healthcare · Industry: Health Information Services · Australia · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.